查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018846

感染疾病疫苗市場：2026-2032年全球市場預測（依疫苗類型、給藥途徑、最終用戶和通路分類）

Infectious Vaccines Market by Vaccine Type, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年感染疾病疫苗市值為348.8億美元，預計到2026年將成長至382.3億美元，複合年成長率為9.76%，到2032年將達到669.8億美元。

主要市場統計數據
基準年 2025 348.8億美元
預計年份：2026年 382.3億美元
預測年份 2032 669.8億美元
複合年成長率 (%) 9.76%

簡單介紹科學進步和營運演變如何改變感染疾病疫苗的研發過程和供應模式。

在科學創新、公共衛生重點轉變和不斷發展的操作實踐的推動下，感染疾病疫苗領域正在經歷一場變革。在過去十年間，mRNA和病毒載體等平台技術的進步已從實驗方法發展成為臨床驗證的工具，並在整體的預防和治療領域引起了廣泛關注。同時，結合疫苗、去活化疫苗、減毒疫苗、次單元和類毒素疫苗等現有方法也透過製劑改進、聯合策略和標靶抗原設計不斷發展。

本文探討了技術、監管和分銷變革如何共同推動疫苗研發和部署實踐的快速發展。

感染疾病疫苗的格局正在重塑，這不僅得益於科學突破，也得益於一系列相互交織的變革，這些變革影響著監管預期、供應鏈網路和醫療服務模式。首先，平台多樣化正在加速。傳訊RNA（mRNA）技術和病毒載體正從概念驗證（PoC）階段邁向大規模生產，而自擴增RNA（saRNA）和改良的脂質體配方則正在拓展其適用範圍。成熟的平台，例如結合疫苗、不活化疫苗和類毒素疫苗，也並未停滯不前。它們正受益於抗原工程（可增強免疫抗原性和持久性）、佐劑最佳化以及新的給藥形式。

對 2025 年關稅措施將如何重塑疫苗生產和分銷的供應鏈、籌資策略和採購趨勢進行現實評估。

2025年起實施的關稅將影響疫苗原料、組件及相關耗材，為生產商、經銷商和採購機構帶來了新的營運挑戰。關稅政策影響整個價值鏈的單位成本結構，促使生產商重新評估其全球籌資策略，盡可能優先考慮本地生產，並加快供應商選擇流程以增強供應韌性。同時，採購機構和公共衛生採購負責人也積極應對，審查供應商多元化策略，並更加重視合約保障措施，以降低供應中斷的風險。

詳細的細分分析揭示了疫苗平台選擇、給藥途徑、最終用戶環境和分銷管道如何相互作用並影響部署結果。

細分市場層面的趨勢反映出疫苗類型、給藥途徑、最終用戶和分銷管道之間存在顯著差異，因此了解這些差異對於策略優先排序至關重要。無論疫苗類型如何，結合疫苗（例如Hib結合疫苗、腦膜炎雙球菌結合疫苗和肺炎球菌結合疫苗）在兒童和高風險成人免疫計劃中仍然至關重要，因為這些計劃優先考慮長期免疫抗原性和群體免疫。去活化疫苗（包括甲型肝炎疫苗、流感疫苗、脊髓灰質炎疫苗和狂犬病疫苗）由於其已確立的安全性以及廣泛的監管認可，仍被廣泛使用。減毒活病毒疫苗減毒活病毒疫苗（例如流感疫苗、麻疹脊髓灰質炎、口服小兒麻痺疫苗、德國德國麻疹和水痘疫苗）可提供強大的免疫反應，並在大規模免疫宣傳活動中發揮核心作用，但需要小心處理和低溫運輸管理。 mRNA技術（分為脂質奈米顆粒mRNA和自擴增mRNA）由於其開發速度快和抗原設計柔軟性，正在迅速擴展到新的適應症。次單元疫苗，例如蛋白質次單元和類病毒顆粒（VLPs），具有更高的安全性和生產便利性。同時，針對白喉、百日咳和破傷風的類毒素疫苗仍然是許多疫苗接種計畫的支柱。腺病毒、MVA 和 VSV 等病毒載體因其能夠誘導強大的細胞免疫，在疾病預防和治療中仍被廣泛應用。

解釋美洲、歐洲、中東和非洲以及亞太地區不同的醫療保健基礎設施和法規環境如何影響疫苗策略的關鍵區域因素。

區域趨勢對產品設計、監管策略、製造地和部署重點都有顯著影響。在美洲，完善的免疫接種計劃和發達的公立及私立醫療衛生基礎設施為醫院藥房、廣泛的零售藥房和線上藥房網路等先進配銷通路提供了支持，同時也為下一代平台和成人免疫接種舉措提供了沃土。因此，開發人員通常會優先考慮符合監管要求和與支付方合作的策略，這些策略既體現了民營市場機制，也體現了大規模公共衛生採購流程。

從策略角度概述公司和合作夥伴如何調整其平台投資、製造能力和協作生態系統，以確保競爭優勢。

生物製藥、生物技術和契約製造領域的領先企業正透過平台投資、策略聯盟和擴大產能來重新定義其競爭地位。一些研發公司專注於平台擴充性，這意味著它們正在建構將mRNA、病毒載體或蛋白質次單元平台應用於多種適應症的能力，以最大限度地提高研發效率。合約研發生產機構（CDMO）正在擴展其填充、包裝和模組化生產能力，以滿足對傳統疫苗和新型疫苗的需求，同時專注於低溫運輸創新和一次性使用技術。

透過結合平台柔軟性、製造韌性和有針對性的商業性參與，為加速採用和降低營運風險提供切實可行的建議。

產業領導者應採取多管齊下的策略，平衡技術創新、業務永續營運和市場驅動的部署。優先考慮平台柔軟性，使企業能夠靈活地將研發資源分配到不同適應症，並快速應對新出現的病原體威脅。同時，投資於製造韌性，例如本地化生產、多元化的供應商網路以及模組化的填充和包裝能力，可以降低因關稅等外部衝擊和成本波動帶來的風險。領導者也應重視給藥途徑的創新，這些創新可以降低物流複雜性、提高病患接受度，或在當地社區推廣無針給藥方案。

對用於評估整個疫苗計劃的平台性能、供應鏈風險和相關人員細分的調查來源和分析方法進行透明的總結。

本研究整合了公開的科學文獻、監管指導文件、產業技術報告以及對研發、生產、法規遵循和採購領域專家的結構化訪談。透過與疫苗研發負責人、契約製造組織 (CMO)、供應鏈專家和公共衛生採購負責人的討論，收集了關鍵的定性數據，以了解實際情況和策略重點。輔助研究包括同行評審期刊、監管公告和技術白皮書，重點關注平台技術、給藥途徑和分銷創新。

一項權威的綜合分析強調了整合科學、製造和商業策略的必要性，以將技術進步轉化為實際的公共衛生成果。

感染疾病疫苗正處於科學、政策和物流快速發展的十字路口，其成功取決於技術能力與切實可行的供應策略的整合。從結合疫苗和去活化疫苗到mRNA疫苗、病毒載體疫苗、次單位疫苗和類毒素疫苗，多種平台為滿足未被滿足的需求提供了多種途徑。同時，給藥途徑的創新為提高人群保護水準和簡化疫苗部署提供了可能。然而，這些科學機會必須與低溫運輸限制、採購機制和監管環境等現實因素平衡。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：感染疾病疫苗市場：依疫苗類型分類

  • 組合型
    • Hib 組合型
    • 腦膜炎雙球菌結合物
    • 肺炎鏈球菌結合物
  • 失活
    • 甲型肝炎
    • 流感
    • 脊髓灰質炎
    • 狂犬病
  • 活病毒疫苗
    • 流感（活病毒疫苗）
    • 麻疹
    • 口服脊髓灰質炎
    • 德國麻疹
    • 水痘
  • mRNA
    • 脂質奈米顆粒mRNA
    • 自擴增mRNA
  • 次單元
    • 蛋白質次單元
    • 類病毒顆粒
  • 類毒素
    • 白喉
    • 百日咳
    • 破傷風
  • 病毒載體
    • 腺病毒
    • MVA
    • VSV

第9章：感染疾病疫苗市場：依給藥途徑分類

  • 皮內注射
  • 肌肉內部
  • 鼻內
  • 口服
  • 皮下

第10章：感染疾病疫苗市場：依最終用戶分類

  • 診所
    • 一般醫療
    • 專業
  • 醫院
    • 私人的
    • 一般的
  • 藥局
    • 線上
    • 零售
  • 公共衛生中心
    • 地區
    • 都市區

第11章：感染疾病疫苗市場：依分銷管道分類

  • 政府機構
    • 地區
    • 國內的
  • 醫院藥房
    • 在醫院裡
    • 門診
  • 網路藥房
    • 直銷
    • 平台
  • 零售藥房
    • 鏈
    • 獨立的

第12章：感染疾病疫苗市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：感染疾病疫苗市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：感染疾病疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國感染疾病疫苗市場

第16章：中國感染疾病疫苗市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Adimmune Corporation
  • AstraZeneca plc
  • Bavarian Nordic
  • Bharat Biotech
  • Biological E Limited
  • BioNTech SE
  • CanSino Biologics
  • China National Biotechnology Group
  • CSL Limited
  • Dynavax Technologies
  • Emergent BioSolutions, Inc.
  • Genocea Biosciences
  • GlaxoSmithKline plc
  • Haffkine Bio-Pharmaceutical Corporation
  • Inovio Pharmaceuticals
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Microgen
  • Mitsubishi Tanabe Pharma
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Serum Institute of India
  • Sinovac Biotech Ltd.
  • Valneva SE
  • Vaxcyte, Inc.
  • VBI Vaccines, Inc.
Product Code: MRR-ED54C46E8F6D

The Infectious Vaccines Market was valued at USD 34.88 billion in 2025 and is projected to grow to USD 38.23 billion in 2026, with a CAGR of 9.76%, reaching USD 66.98 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 34.88 billion
Estimated Year [2026] USD 38.23 billion
Forecast Year [2032] USD 66.98 billion
CAGR (%) 9.76%

A concise introduction outlining how scientific advances and operational evolution are reshaping infectious vaccine development pathways and delivery models

The infectious vaccines landscape is undergoing a transformative phase driven by scientific innovation, evolving public health priorities, and shifting operational practices. Over the last decade, advances in platform technologies such as mRNA and viral vectors have matured from experimental modalities into clinically validated tools, prompting broader interest across preventive and therapeutic indications. Concurrently, established modalities including conjugate, inactivated, live attenuated, subunit, and toxoid vaccines continue to evolve through formulation improvements, combination strategies, and targeted antigen design.

Emerging manufacturing techniques, improved cold chain management, and digital supply chain visibility are enabling more reliable distribution across diverse healthcare settings. Regulatory pathways are adapting to accommodate novel platforms while maintaining rigorous safety and efficacy standards, and public health programs are increasingly prioritizing broader vaccine access and adult immunization strategies. As a result, stakeholders from biopharma developers to public immunization programs are recalibrating product development, partnership, and deployment plans to reflect both technological promise and operational realities.

This introduction frames the report's focus on platform diversity, route-of-administration innovation, end-user dynamics across clinics, hospitals, pharmacies, and public health centers, and the distribution mechanisms that will shape uptake and impact. It sets the scene for detailed analysis that follows, identifying where scientific opportunity intersects with commercial and public health imperatives.

An exploration of converging technological, regulatory, and distributional shifts that are driving rapid evolution in vaccine development and deployment practices

The landscape for infectious vaccines is being reshaped by a set of converging shifts that extend beyond scientific breakthroughs to influence regulatory expectations, supply networks, and care delivery models. First, platform diversification is accelerating: messenger RNA technologies and viral vectors have moved from proof-of-concept to scalable manufacturing, while self-amplifying RNA and refined lipid nanoparticle formulations are increasing the range of feasible indications. Established platforms such as conjugate, inactivated, and toxoid vaccines are not standing still; they are benefitting from antigen engineering, adjuvant optimization, and novel presentation formats that improve immunogenicity and durability.

Second, administration routes are expanding in importance. Intramuscular delivery remains dominant for many programs, yet intradermal, intranasal, oral, and subcutaneous options are attracting renewed attention because they can improve patient acceptance, simplify logistics, or confer mucosal immunity. Third, end-user segmentation is influencing distribution strategies: clinics, hospitals, pharmacies, and public health centers each present distinct operational constraints and opportunities, shaping packaging, cold chain requirements, and digital record integration. Fourth, distribution channels are fragmenting and specializing, with government procurement, hospital pharmacies, online pharmacies, and retail outlets each requiring tailored commercial approaches.

Together, these shifts create a dynamic environment where agility in development and distribution, coupled with strategic partnerships and regulatory foresight, will determine which programs achieve broad and sustained adoption.

A pragmatic assessment of how 2025 tariff measures are reshaping supply chains, sourcing strategies, and procurement dynamics across vaccine manufacturing and distribution

The introduction of tariffs affecting vaccine inputs, components, and related consumables in 2025 has introduced a new operational variable for manufacturers, distributors, and procurement agencies. Tariff policies influence unit cost structures across the value chain, driving manufacturers to re-evaluate global sourcing strategies, prioritize localized production where feasible, and accelerate supplier qualification processes to maintain resilience. In parallel, procurement organizations and public health purchasers have responded by reassessing supplier diversification and by placing greater emphasis on contractual safeguards to mitigate supply disruptions.

Tariffs also affect the economics of distribution channels. Hospital pharmacies, retail and online pharmacies, and government procurement entities must integrate additional cost and compliance considerations into purchasing decisions, which can alter relative attractiveness of imported versus domestically produced products. For clinical developers, the cumulative cost effects have incentivized consideration of regional manufacturing partnerships and technology transfer agreements to reduce exposure to tariff-related volatility.

From a downstream perspective, routes of administration that reduce reliance on specialized cold chain components or disposable delivery devices may gain pragmatic appeal because they can lower the exposure to tariff-driven cost increases for ancillary supplies. Overall, the tariff landscape in 2025 underscores the importance of supply chain transparency, contractual flexibility, and proactive engagement with procurement bodies to preserve access while protecting margins and continuity of supply.

In-depth segmentation insights revealing how vaccine platform choices, administration routes, end-user settings, and distribution channels interact to shape adoption outcomes

Segment-level dynamics reflect pronounced heterogeneity across vaccine types, administration routes, end users, and distribution channels, and understanding these distinctions is essential for strategic prioritization. Across vaccine types, conjugate approaches-spanning Hib conjugate, meningococcal conjugate, and pneumococcal conjugate formats-remain essential for pediatric and high-risk adult programs where long-term immunogenicity and herd protection are priorities. Inactivated platforms, including hepatitis A, influenza, polio, and rabies formulations, continue to be widely used due to established safety profiles and broad regulatory familiarity. Live attenuated vaccines such as influenza live formulations, measles, oral polio, rubella, and varicella offer potent immune responses and are central to mass immunization campaigns but require careful handling and cold chain management. mRNA technologies, differentiated into lipid nanoparticle mRNA and self-amplifying mRNA, are rapidly expanding into new indications because of their development speed and antigen design flexibility. Subunit approaches, including protein subunit and virus-like particle constructs, provide attractive safety and manufacturability attributes, while toxoid vaccines targeting diphtheria, pertussis, and tetanus remain pillars of many immunization schedules. Viral vectors such as adenovirus, MVA, and VSV continue to be leveraged for their ability to elicit strong cellular immunity in both prophylactic and therapeutic contexts.

When considering routes of administration, intradermal, intramuscular, intranasal, oral, and subcutaneous options create differing operational demands and patient experiences that influence adoption in clinics, hospitals, pharmacies, and public health centers. End-user settings vary widely: clinics encompassing general practice and specialty care have different throughput and storage needs compared with hospitals, where private and public institutions have distinct procurement and formulary processes; pharmacies operate across online and retail formats with unique customer interfaces; and public health centers in rural and urban settings confront divergent logistical constraints. Distribution channels-government agencies divided into local and national tiers, hospital pharmacies operating in-hospital and outpatient services, online pharmacies delivering direct and platform-mediated sales, and retail pharmacies split between chain and independent models-further shape commercial approaches. These segmentation dimensions interact; for example, a protein subunit vaccine delivered intramuscularly for adult use may follow a distinct distribution and procurement path than an intranasal live attenuated pediatric vaccine procured through national public health tenders.

Recognizing these interdependencies enables stakeholders to align development, manufacturing, and commercialization strategies with the specific requirements of target segments, reducing time to adoption and enhancing operational fit.

Key regional considerations explaining how distinct healthcare infrastructures and regulatory environments in the Americas, EMEA, and Asia-Pacific shape vaccine strategy

Regional dynamics exert a strong influence on product design, regulatory strategy, manufacturing footprint, and deployment priorities. In the Americas, established immunization programs and well-developed private and public healthcare infrastructures support advanced distribution channels such as hospital pharmacies and extensive retail and online pharmacy networks, while also providing fertile ground for next-generation platforms and adult immunization initiatives. Consequently, developers often prioritize regulatory alignment and payer engagement strategies that reflect both private market mechanisms and large-scale public health procurement processes.

Europe, Middle East & Africa present a mosaic of regulatory frameworks, public health priorities, and supply chain capabilities. In parts of Europe, sophisticated regulatory pathways and manufacturing clusters allow for rapid adoption of novel platforms, whereas regions across the Middle East and Africa may prioritize thermostable formulations, simplified administration routes, and partnership models that support local capacity building to address access constraints. Public health centers in rural and urban areas across this region demand flexible cold chain solutions and deployment strategies that can operate under variable infrastructure conditions.

Asia-Pacific encompasses a wide spectrum from advanced manufacturing hubs to rapidly developing public health systems. Countries with strong biotech ecosystems are investing heavily in mRNA, viral vector, and next-generation manufacturing capabilities, while others focus on broadening routine immunization with established conjugate, inactivated, and toxoid vaccines. Across the region, there is heightened interest in technologies and distribution models that reduce supply chain vulnerability, enable local production, and support rapid scale-up during outbreaks. Taken together, regional priorities influence product specifications, regulatory timelines, and supply chain investments, making geographic strategy a central component of any vaccine program.

A strategic synthesis of how companies and partners are aligning platform investments, manufacturing capabilities, and collaborative ecosystems to secure competitive advantage

Leading organizations across biopharma, biotech, and contract manufacturing are redefining competitive positioning through combinations of platform investment, strategic alliances, and capacity expansion. Some developers are focusing on platform extensibility, meaning they are building capabilities to repurpose mRNA, viral vector, or protein subunit platforms for multiple indications to maximize development efficiency. Contract development and manufacturing organizations are expanding fill-finish and modular production capabilities to meet demand for both traditional and novel vaccine formats, with attention to cold chain innovations and single-use technologies.

Collaborative ecosystems are increasingly central: alliances between large pharmaceutical companies, regional manufacturers, and technology specialists facilitate technology transfer, local production, and regulatory navigation. In parallel, specialized suppliers of lipid nanoparticles, adjuvants, and analytical services are gaining importance as strategic partners because they provide critical inputs that affect product performance and manufacturability. Clinical and regulatory consultancies that can support accelerated clinical pathways and dossier preparation across diverse jurisdictions are also valued partners.

Finally, surveillance and real-world evidence providers that integrate immunization registries, adverse event monitoring, and epidemiological data are becoming strategic assets for companies seeking to demonstrate value, optimize post-approval programs, and support targeted vaccination campaigns. Collectively, these trends underscore the need for a coordinated approach to partnerships, capacity planning, and technology investment to maintain competitiveness in a complex and fast-evolving landscape.

Actionable recommendations that combine platform flexibility, manufacturing resilience, and targeted commercial engagement to enhance adoption and mitigate operational risk

Industry leaders should adopt a multi-dimensional strategy that balances technological innovation, operational resilience, and market-tailored deployment. Prioritizing platform flexibility enables organizations to pivot development resources across indications and respond quickly to emerging pathogen threats. At the same time, investing in manufacturing resilience - including localized production, diversified supplier networks, and modular fill-finish capacity - reduces exposure to external shocks and tariff-driven cost variability. Leaders should also evaluate route-of-administration innovations that can lower logistics complexity, improve patient acceptance, or enable needle-free delivery programs in community settings.

Commercially, aligning distribution strategies with the needs of specific end users and channels will accelerate adoption. For instance, engaging early with hospital formulary committees, retail pharmacy chains, and public health purchasers can clarify storage and packaging requirements and inform pricing and contracting approaches. Regulatory foresight is equally important: proactive dialogue with authorities and investment in harmonized dossier development expedite approvals across multiple jurisdictions. Finally, establishing data partnerships for post-market surveillance and real-world effectiveness monitoring strengthens value demonstrations and supports sustained uptake.

By combining platform versatility, supply chain robustness, targeted commercial engagement, and evidence-generation commitments, industry leaders can position their portfolios to capture clinical and public health opportunities while mitigating operational risks.

A transparent summary of research sources and analytical approaches used to evaluate platform performance, supply chain risks, and stakeholder segmentation across vaccine programs

This research synthesizes public scientific literature, regulatory guidance documents, industry technical reports, and structured interviews with subject-matter experts across development, manufacturing, regulatory affairs, and procurement. Primary qualitative inputs were collected through discussions with leaders in vaccine development, contract manufacturing organizations, supply chain specialists, and public health procurement officers to capture operational realities and strategic priorities. Secondary research encompassed peer-reviewed journals, regulatory agency communications, and technical white papers focused on platform technologies, administration routes, and distribution innovations.

Analysis methodologies included comparative platform assessment, supply chain risk mapping, and stakeholder segmentation to identify critical interdependencies among vaccine types, routes of administration, end-user requirements, and distribution channels. Scenario-based evaluation was applied to assess the operational implications of policy changes such as tariff measures, and to explore strategic responses including localization, supplier diversification, and alternative packaging strategies. Wherever possible, findings were cross-validated across multiple sources to ensure robustness, and expert validation sessions were conducted to refine key insights and practical recommendations.

This approach provides a holistic view of technological potential, operational constraints, and commercial pathways without relying on proprietary market estimates, enabling decision-makers to draw practical conclusions for strategy and investment.

A conclusive synthesis emphasizing the need for integrated scientific, manufacturing, and commercial strategies to convert technology advances into reliable public health impact

Infectious vaccines occupy a rapidly evolving intersection of science, policy, and logistics, where success depends on integrating technological capabilities with pragmatic delivery strategies. Platform diversity-from conjugate and inactivated vaccines to mRNA, viral vectors, subunit constructs, and toxoids-offers multiple pathways to address unmet needs, while administration route innovations open possibilities for improved population-level protection and easier deployment. However, these scientific opportunities must be balanced against operational realities including cold chain constraints, procurement mechanisms, and the regulatory landscape.

The cumulative impact of policy actions, such as the tariff measures introduced in 2025, highlights the need for supply chain transparency and flexible sourcing approaches. Regional differences in infrastructure and regulatory maturity further underscore the importance of tailoring strategies to geographic context. Ultimately, organizations that align platform selection with end-user needs, invest in resilient and scalable manufacturing, and engage proactively with payers and public health stakeholders will be best positioned to translate scientific advances into widespread, sustainable public health impact.

This conclusion emphasizes the imperative for coordinated action across R&D, manufacturing, and commercial functions to realize the potential of next-generation vaccines while ensuring equitable and reliable access.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Infectious Vaccines Market, by Vaccine Type

  • 8.1. Conjugate
    • 8.1.1. Hib Conjugate
    • 8.1.2. Meningococcal Conjugate
    • 8.1.3. Pneumococcal Conjugate
  • 8.2. Inactivated
    • 8.2.1. Hepatitis A
    • 8.2.2. Influenza
    • 8.2.3. Polio
    • 8.2.4. Rabies
  • 8.3. Live Attenuated
    • 8.3.1. Influenza Laiv
    • 8.3.2. Measles
    • 8.3.3. Oral Polio
    • 8.3.4. Rubella
    • 8.3.5. Varicella
  • 8.4. MRNA
    • 8.4.1. Lipid Nanoparticle MRNA
    • 8.4.2. Self-Amplifying MRNA
  • 8.5. Subunit
    • 8.5.1. Protein Subunit
    • 8.5.2. Virus-Like Particle
  • 8.6. Toxoid
    • 8.6.1. Diphtheria
    • 8.6.2. Pertussis
    • 8.6.3. Tetanus
  • 8.7. Viral Vector
    • 8.7.1. Adenovirus
    • 8.7.2. MVA
    • 8.7.3. VSV

9. Infectious Vaccines Market, by Route Of Administration

  • 9.1. Intradermal
  • 9.2. Intramuscular
  • 9.3. Intranasal
  • 9.4. Oral
  • 9.5. Subcutaneous

10. Infectious Vaccines Market, by End User

  • 10.1. Clinics
    • 10.1.1. General Practice
    • 10.1.2. Specialty
  • 10.2. Hospitals
    • 10.2.1. Private
    • 10.2.2. Public
  • 10.3. Pharmacies
    • 10.3.1. Online
    • 10.3.2. Retail
  • 10.4. Public Health Centers
    • 10.4.1. Rural
    • 10.4.2. Urban

11. Infectious Vaccines Market, by Distribution Channel

  • 11.1. Government Agencies
    • 11.1.1. Local
    • 11.1.2. National
  • 11.2. Hospital Pharmacies
    • 11.2.1. In-Hospital
    • 11.2.2. Outpatient
  • 11.3. Online Pharmacies
    • 11.3.1. Direct
    • 11.3.2. Platform
  • 11.4. Retail Pharmacies
    • 11.4.1. Chain
    • 11.4.2. Independent

12. Infectious Vaccines Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Infectious Vaccines Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Infectious Vaccines Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Infectious Vaccines Market

16. China Infectious Vaccines Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Adimmune Corporation
  • 17.6. AstraZeneca plc
  • 17.7. Bavarian Nordic
  • 17.8. Bharat Biotech
  • 17.9. Biological E Limited
  • 17.10. BioNTech SE
  • 17.11. CanSino Biologics
  • 17.12. China National Biotechnology Group
  • 17.13. CSL Limited
  • 17.14. Dynavax Technologies
  • 17.15. Emergent BioSolutions, Inc.
  • 17.16. Genocea Biosciences
  • 17.17. GlaxoSmithKline plc
  • 17.18. Haffkine Bio-Pharmaceutical Corporation
  • 17.19. Inovio Pharmaceuticals
  • 17.20. Johnson & Johnson
  • 17.21. Merck & Co., Inc.
  • 17.22. Microgen
  • 17.23. Mitsubishi Tanabe Pharma
  • 17.24. Moderna, Inc.
  • 17.25. Novavax, Inc.
  • 17.26. Pfizer Inc.
  • 17.27. Sanofi S.A.
  • 17.28. Serum Institute of India
  • 17.29. Sinovac Biotech Ltd.
  • 17.30. Valneva SE
  • 17.31. Vaxcyte, Inc.
  • 17.32. VBI Vaccines, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INFECTIOUS VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INFECTIOUS VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HIB CONJUGATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HIB CONJUGATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HIB CONJUGATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MENINGOCOCCAL CONJUGATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MENINGOCOCCAL CONJUGATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MENINGOCOCCAL CONJUGATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PNEUMOCOCCAL CONJUGATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PNEUMOCOCCAL CONJUGATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PNEUMOCOCCAL CONJUGATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HEPATITIS A, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HEPATITIS A, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HEPATITIS A, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY POLIO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY POLIO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY POLIO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RABIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RABIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RABIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA LAIV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA LAIV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA LAIV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MEASLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MEASLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MEASLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL POLIO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL POLIO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL POLIO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RUBELLA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RUBELLA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RUBELLA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VARICELLA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VARICELLA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIPID NANOPARTICLE MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIPID NANOPARTICLE MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIPID NANOPARTICLE MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRUS-LIKE PARTICLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRUS-LIKE PARTICLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRUS-LIKE PARTICLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DIPHTHERIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DIPHTHERIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DIPHTHERIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PERTUSSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PERTUSSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PERTUSSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TETANUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TETANUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TETANUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VSV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VSV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VSV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRADERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GENERAL PRACTICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GENERAL PRACTICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GENERAL PRACTICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SPECIALTY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SPECIALTY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SPECIALTY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PRIVATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RETAIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RETAIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RETAIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RURAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RURAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RURAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY URBAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY URBAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY URBAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LOCAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LOCAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LOCAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY NATIONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY NATIONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY NATIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY IN-HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY IN-HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY IN-HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DIRECT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DIRECT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DIRECT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PLATFORM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PLATFORM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PLATFORM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CHAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CHAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CHAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INDEPENDENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INDEPENDENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INDEPENDENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 196. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 197. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 199. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 200. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 201. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 202. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 203. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 204. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 205. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 208. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 209. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 210. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 211. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2032 (USD MILLION)
  • TABLE 213. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 214. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 215. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 216. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 220. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 222. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 224. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 226. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 228. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 230. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 234. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 236. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 240. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 242. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 244. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 246. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 248. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 250. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 254. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 296. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 300. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 302. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 304. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 306. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 308. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 310. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 312. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 314. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 316. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 317. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 319. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 320. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 321. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 322. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 323. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 324. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 325. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 326. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 327. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 328. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 329. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 330. AFRICA INFECTIOUS VACCI